Second Amendment to Exclusive Patent License Agreement Between University of Arizona and Oncothyreon, Inc. Effective 15 September 2005Exclusive Patent License Agreement • March 14th, 2011 • Oncothyreon Inc. • Services-commercial physical & biological research
This Second Amendment (“Second Amendment”), effective on the date of last authorized signature affixed hereto, is by and between the Arizona Board of Regents on behalf of the University of Arizona, having an office at 888 N. Euclid Avenue, Room 204, Tucson, Arizona 85721 (“LICENSOR”), and Oncothyreon, Inc., having its principal office at 2601 Fourth Avenue, Suite 500, Seattle, Washington 98121 (“LICENSEE”).
First Amendment to Exclusive License Agreement Between University of Arizona and Oncothyreon, Inc., Effective 29 July 2004Exclusive License Agreement • March 14th, 2011 • Oncothyreon Inc. • Services-commercial physical & biological research
This First Amendment (“Amendment”), effective on the date of last authorized signature affixed hereto (“Amendment Effective Date”), is by and between the Arizona Board of Regents on behalf of the University of Arizona, having an office at 888 N. Euclid Avenue, Room 204, Tucson, Arizona 85721 (“LICENSOR”), and Oncothyreon, Inc., having its principal office at 2601 Fourth Avenue, Suite 500, Seattle, Washington 98121 (“LICENSEE”).
First Amendment to Exclusive License Agreement between The University of Arizona and ProlX PHARMACEUTICALS, Inc. Effective September 15, 2005Exclusive License Agreement • March 14th, 2011 • Oncothyreon Inc. • Services-commercial physical & biological research
This First Amendment to the Exclusive License Agreement between Prolx Pharmaceuticals, Inc., now Oncothyreon, Inc. (“LICENSEE”), and the Arizona Board of Regents on behalf of the University of Arizona (“LICENSOR”) for an invention entitled “Method of Preselecting Patients for Anti-VEGF, Anti-HIF-1 or Anti-Thioredoxin Therapy” (“Agreement”) is made effective as of the date of the last authorized signature below.
